Literature DB >> 17151112

Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations.

David K Clarke1, Farooq Nasar, Margaret Lee, J Erik Johnson, Kevin Wright, Priscilla Calderon, Min Guo, Robert Natuk, David Cooper, R Michael Hendry, Stephen A Udem.   

Abstract

A variety of rational approaches to attenuate growth and virulence of vesicular stomatitis virus (VSV) have been described previously. These include gene shuffling, truncation of the cytoplasmic tail of the G protein, and generation of noncytopathic M gene mutants. When separately introduced into recombinant VSV (rVSV), these mutations gave rise to viruses distinguished from their "wild-type" progenitor by diminished reproductive capacity in cell culture and/or reduced cytopathology and decreased pathogenicity in vivo. However, histopathology data from an exploratory nonhuman primate neurovirulence study indicated that some of these attenuated viruses could still cause significant levels of neurological injury. In this study, additional attenuated rVSV variants were generated by combination of the above-named three distinct classes of mutation. The resulting combination mutants were characterized by plaque size and growth kinetics in cell culture, and virulence was assessed by determination of the intracranial (IC) 50% lethal dose (LD(50)) in mice. Compared to virus having only one type of attenuating mutation, all of the mutation combinations examined gave rise to virus with smaller plaque phenotypes, delayed growth kinetics, and 10- to 500-fold-lower peak titers in cell culture. A similar pattern of attenuation was also observed following IC inoculation of mice, where differences in LD(50) of many orders of magnitude between viruses containing one and two types of attenuating mutation were sometimes seen. The results show synergistic rather than cumulative increases in attenuation and demonstrate a new approach to the attenuation of VSV and possibly other viruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151112      PMCID: PMC1797571          DOI: 10.1128/JVI.01911-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

Review 1.  Innate immune responses in viral encephalitis.

Authors:  C S Reiss; D A Chesler; J Hodges; D D C Ireland; N Chen
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

Review 2.  The role of IFN-gamma in immune responses to viral infections of the central nervous system.

Authors:  David A Chesler; Carol Shoshkes Reiss
Journal:  Cytokine Growth Factor Rev       Date:  2002-12       Impact factor: 7.638

3.  Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response.

Authors:  E B Flanagan; L A Ball; G W Wertz
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus.

Authors:  S U Emerson; Y Yu
Journal:  J Virol       Date:  1975-06       Impact factor: 5.103

5.  Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus.

Authors:  G W Wertz; V P Perepelitsa; L A Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

6.  Ribonucleic acid synthesis of vesicular stomatitis virus, II. An RNA polymerase in the virion.

Authors:  D Baltimore; A S Huang; M Stampfer
Journal:  Proc Natl Acad Sci U S A       Date:  1970-06       Impact factor: 11.205

7.  Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.

Authors:  L S Wyatt; B Moss; S Rozenblatt
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

8.  Replication and assembly of VSV nucleocapsids: protein association with RNPs and the effects of cycloheximide on replication.

Authors:  C Rubio; C Kolakofsky; V M Hill; D F Summers
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

9.  Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo.

Authors:  B L Black; D S Lyles
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

Review 10.  Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.

Authors:  David K Clarke; David Cooper; Michael A Egan; R Michael Hendry; Christopher L Parks; Stephen A Udem
Journal:  Springer Semin Immunopathol       Date:  2006-09-15
View more
  52 in total

1.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 2.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

3.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

Authors:  Brice Barefoot; Natalie J Thornburg; Daniel H Barouch; Jae-Sung Yu; Christopher Sample; Robert E Johnston; Hua Xin Liao; Thomas B Kepler; Barton F Haynes; Elizabeth Ramsburg
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

6.  Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

Authors:  Marta L Marthas; Koen K A Van Rompay; Zachary Abbott; Patricia Earl; Linda Buonocore-Buzzelli; Bernard Moss; Nina F Rose; John K Rose; Pamela A Kozlowski; Kristina Abel
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

7.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells.

Authors:  Guido Wollmann; Vitaliy Rogulin; Ian Simon; John K Rose; Anthony N van den Pol
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

10.  In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.

Authors:  J Erik Johnson; John W Coleman; Narender K Kalyan; Priscilla Calderon; Kevin J Wright; Jennifer Obregon; Eleanor Ogin-Wilson; Robert J Natuk; David K Clarke; Stephen A Udem; David Cooper; R Michael Hendry
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.